How to tackle new strains of potato blight and avoid another great famine
A new aggressive potato blight strain was detected in Wales and eastern Scotland earlier this year. The strain, identified as EU 46, can withstand certain fungicides, making it harder to control. It serves as a stark reminder that nearly 175 years after Ireland's great famine, this destructive pathogen continues to evolve and endanger crops around the world.
Each year, farmers lose an estimated US$6–7 billion (£4.5-5.2 billion) worth of crops due to this disease. In Europe alone, direct losses and control costs amount to over €1 billion (£800 million) annually. That includes the cost of expensive fungicide sprays that farmers rely on for protection.
In developing countries, the stakes are even higher. Many smallhold farmers lack resources for intensive disease management. In Uganda, potato blight can destroy up to 100% of a farmer's crop, endangering livelihoods and local food security.
Just as in the Irish famine, dependence on a single crop is risky. When blight strikes these vulnerable communities, the consequences can be devastating.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
After decades of research, blight remains hard to defeat, partly due to the pathogen's remarkable adaptability. Over the years, Phytophthora infestans (late blight) has repeatedly evolved new genetic strains that overcome both chemical fungicides and the resistant potato varieties bred to fend it off.
The newly identified EU 46 strain is just one example of how quickly blight can develop resistance. In this case, tolerating a key fungicide and showing reduced sensitivity to others.
Meanwhile, environmental changes and global trade create opportunities for wind-blown spores to migrate into new regions. All of this means farmers must remain vigilant; what worked against blight last year might not work today.
After the Irish famine of the 1840s, science eventually identified its microscopic culprit and ways to fight it, but innovation didn't stop there. Today, researchers and farmers are enlisting cutting-edge technology to stay ahead of blight.
One promising tool is real-time spore detection. Devices like the SwisensPoleno, a monitor developed in Switzerland, can constantly scan the air on farms and spot signs of P. infestans spores as they appear.
In Ireland, I'm leading a project testing this technology out on farms. These sensors rely on advanced imaging and AI to tell blight spores apart from other particles, giving farmers an early warning so they can act before the disease spreads.
Equally, new rapid DNA diagnostics can detect blight more quickly than traditional lab tests which take days to identify new strains. Portable testing kits are bringing diagnostics to the field. My colleagues and I have developed a simple in-field test (like COVID-19 lateral flow tests) that detects specific blight strains from a crushed leaf or air samples in under 30 minutes.
Such tests not only confirm the presence of blight but can tell if the strain is one known to resist certain fungicides. This information allows farmers to choose the right treatment immediately, targeting the pathogen's weaknesses and avoiding wasted effort.
Farmers are also using data and computer modelling to anticipate outbreaks of the disease allowing them to act before it can takes hold. Sophisticated forecasting systems crunch weather data (temperature, humidity, rainfall) and spore counts to predict when and where blight is likely to strike next.
By pinpointing high-risk periods, these models help schedule fungicide applications more strategically – only when needed, rather than on a fixed calendar. This not only cuts costs and environmental damage by reducing unnecessary sprays, but also slows down resistance development in the pathogen.
Defeating potato blight demands international efforts. There's no wonder drug or magic gene that can eliminate this ever-changing pathogen. Like other experts, I advocate for an integrated pest-management approach.
This combines cultural practices (like crop rotation and destroying infected plant debris) alongside biological controls (naturally occurring microbes, like beneficial bacteria, to help suppress the disease and limit its impact on crops). Judicious fungicide use to reduce the chances of blight taking hold is also effective.
Using technology to leverage real-time data enables farmers to act on early warnings and apply treatments in a targeted way, preserving yields while minimising environmental damage.
Investing in research and farmer education is essential too – from developing resistant potato breeds to training farmers in remote areas on how to use new diagnostic kits.
The fight against potato blight is global by necessity. An airborne spore originating in one country can hop to another on the wind, as Europe's experience shows. Likewise, breakthroughs in one lab or farm – whether a new sensor, a resistant potato variety, or an effective organic spray – need to be shared and supported across borders.
International initiatives are putting the latest blight-fighting tools into the hands of farmers around the world. Supporting smallhold farmers in developing countries is especially vital, because they often face blight with limited resources and far more is at stake in terms of food security.
In the mid-19th century, Ireland's potato-dependent society was caught tragically off guard. Today, we have knowledge, technology and hard-earned lessons on our side.
By embracing an integrated, technology driven strategy and ensuring it reaches farmers everywhere, that blight cycle could be broken. The continued emergence of strains like EU 46 is a warning, but also a call to action. One that we are now better equipped than ever to answer.
Get a weekly roundup in your inbox instead. Every Wednesday, The Conversation's environment editor writes Imagine, a short email that goes a little deeper into just one climate issue. Join the 45,000+ readers who've subscribed so far.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
David O'Connor receives funding from Research Ireland and Irish EPA.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Medable launches programme to enhance eCOA build capabilities in clinical trials
US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical outcome assessment (eCOA) build capabilities in digitally enabled studies. The Partner Program runs on the company's platform and aims to enable CROs to reduce clinical trial timelines by at least 50%, providing both administrative and financial benefits. It is also designed to help CROs generate trial-specific quotes rapidly and enter trial kick-off or bid defence meetings with pre-built digital studies. The Partner Program offers CROs a choice between self-service, managed service, or a hybrid support model, with the aim to deliver higher margin services through the use of generative AI. Among the programme's features are tools for pricing, demo support for bid defence meetings, and a content library to facilitate reuse and scalability. One of its key components is access to Studio, Medable's AI-powered tool for creating, storing and reusing eCOA instruments. Studio is designed to allow CROs to build eCOA assessments and deploy trials independently, providing the flexibility they need to scale their operations. Its features include content libraries, a translational workbench, virtual scheduling capabilities, and an AI-based point-and-click builder. Medable chief customer officer Alison Holland said: 'We have created a better buyer experience for CROs while putting powerful generative AI capabilities into their hands to reduce the time to first-patient-in and ensure greater control over the trial build process. 'Medable's Partner Program also simplifies administration and delivers strategic business advantages. Sponsors will want to work with our partners to move closer to Medable's vision of a one-day study start.' Based in California, Medable offers a digital clinical trials platform that has been used in nearly 400 trials across 70 countries to date. The company recently launched a digital-first long-term follow-up model intended to reduce burdens on sites and participants in cell and gene therapy trials. "Medable launches programme to enhance eCOA build capabilities in clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
3 hours ago
- Yahoo
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Mapping Ireland's peatlands to help cut carbon emissions
Mapping more accurately than ever Ireland's peatlands, which are vital as carbon sinks but whose boundaries can be hard to determine, could help fight global warming, researchers say. Ireland is pockmarked with patches of dark brown peat soil that make up at least 20 percent of the land cover, according to Eve Daly, a geophysicist at the University of Galway, who co-led a groundbreaking project on finding peat. "Peatland soils contain comparable amounts of carbon to the likes of rainforests so a more accurate map can lead to better land management decisions and mitigate against greenhouse gas emissions," Daly told AFP. Her research team developed a new mapping approach using gamma radiation measurements to identify for the first time "transition zones" -- typically hidden under forests and grasslands -- where the soil changes from being peat to mineral-based. Daly says the area of soil in Ireland considered "peaty" has increased thanks to a new colour-coded "peat/non-peat" map produced by the researchers. "Improved mapping at higher resolution and locating where hidden organic peat soils are and their extent are key inputs into working out carbon emission factors," she said. Her project co-leader Dave O'Leary told AFP about 80 percent of Ireland had now been mapped out in patches of "peat" brown or "non-peat" green. "Few countries have invested in such an incredible data set, which puts Ireland at the forefront of peatland mapping research," he said. - 'New lens' - Land use, including farming and peatland draining, is a major source of Ireland's carbon emissions which could see the country failing to meet an EU-agreed climate target to cut emissions by over 50 percent by 2030. A recent report said Ireland risks an EU fine of almost 30 billion euros if it fails to reach the target and recommended the restoring -- and rewetting -- of thousands of hectares of peatlands to help deliver "massive" cuts in emissions. "We need to use more modern technologies or use old technologies with new lenses to try and find these hidden peat soils," Daly said. Ireland's boggy areas are typically located in the middle of the bowl-shaped country which is ringed with hills and low mountains around the coastal areas. Triven Koganti, an agroecology expert at Denmark's Aarhus University, told AFP that five percent of global greenhouse gas emissions came from cultivated peatlands. "Historical agricultural draining of peatlands... or to use them as a fuel source has led to significant greenhouse gas emissions," he said. So "an accurate accounting" of peatland boundaries is needed to achieve "current global initiatives to restore peatlands", he said, adding the Irish research "plays an important role in establishing this". - 'Bird's eye' technique - The mapping technique -- described as "bird's eye" by Daly -- is based on gamma-ray data measured by a sensor onboard a plane that has been flown low over Ireland for a decade in a state-funded geophysical survey. "All rocks and different amounts of soils give off a certain amount of natural radiation but peat doesn't as it's full of organic material," Daly said. Soils are usually a mixture of broken bits of rock, water and air, but peat soils are distinct from mineral soils as they are formed from decaying plant material, water and air, and contain a very high amount of carbon. When waterlogged, this carbon is stored in the soil but when water is removed, for example via drainage, peat soils then emit carbon dioxide as the decay process restarts, Daly said. The state-funded "Tellus" survey began in 2011 and is expected to be completed later this year. pmu/jkb/giv/dhw